HOTH Hoth Therapeutics, Inc. Stock Quote

HOTH [NASD]

Index	-	P/E	-	EPS (ttm)	-0.53	Insider Own	2.73%	Shs Outstand	23.98M	Perf Week	-0.74%
Market Cap	13.50M	Forward P/E	-	EPS next Y	-0.38	Insider Trans	0.00%	Shs Float	23.32M	Perf Month	-4.62%
Income	-12.60M	PEG	-	EPS next Q	-0.10	Inst Own	8.30%	Short Float	0.50%	Perf Quarter	-40.03%
Sales	-	P/S	-	EPS this Y	-10.10%	Inst Trans	3.21%	Short Ratio	0.03	Perf Half Y	-39.94%
Book/sh	0.33	P/B	1.26	EPS next Y	-	ROA	-95.00%	Target Price	3.00	Perf Year	-74.38%
Cash/sh	0.26	P/C	1.63	EPS next 5Y	-	ROE	-105.90%	52W Range	0.38 - 1.75	Perf YTD	-37.11%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-76.29%	Beta	1.02
Dividend %	-	Quick Ratio	10.30	Sales past 5Y	-	Gross Margin	-	52W Low	9.21%	ATR	0.03
Employees	4	Current Ratio	10.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	46.28	Volatility	8.39% 7.78%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	55.50%	Profit Margin	-	Rel Volume	0.06	Prev Close	0.42
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	3.99M	Price	0.41
Recom	2.00	SMA20	-0.19%	SMA50	-10.44%	SMA200	-44.02%	Volume	249,280	Change	-1.00%

Oct-15-19

Initiated

The Benchmark Company

Speculative Buy

$10

Jun-29-22 01:25PM	Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price Rule PR Newswire
Jun-21-22 12:30PM	Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis PR Newswire
Jun-15-22 12:30PM	Hoth Announces Adjournment of Annual Meeting of Shareholders Until June 23, 2022 PR Newswire
Jun-09-22 08:18AM	Hoth Therapeutics Announces Extension of Washington University Alzheimer's Mouse Model Study with Alzheimer's Therapeutic HT-ALZ PR Newswire
May-06-22 09:02AM	10 Biotech Penny Stocks Redditors Love Insider Monkey
May-03-22 08:09AM	Hoth Therapeutics Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic Dermatitis Patient Cohort PR Newswire
Apr-19-22 03:29PM	Hoth Therapeutics Adds New Pipeline Program For Stroke, Brain Injury Benzinga
10:29AM	Hoth Therapeutics Announces New Pipeline Asset, HT-TBI for Stroke and Traumatic Brain Injury PR Newswire
Apr-14-22 01:02PM	Hoth Therapeutics, Inc. Announces Closing of $7.0 Million Underwritten Public Offering Priced At-The-Market PR Newswire +6.15%
Apr-12-22 08:17AM	Hoth Therapeutics Announces Acceptance to Present HT-ALZ Proof-of-Concept Alzheimer's Disease Data at the 2022 Alzheimer's Association International Conference PR Newswire -31.43%
Apr-11-22 11:31PM	Hoth Therapeutics, Inc. Announces Pricing of $7.0 Million Underwritten Public Offering Priced At-The-Market PR Newswire +70.48%
04:21PM	Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock PR Newswire
03:49PM	Pair of Drugmakers Soar in Meme-Like Session on Study Results Bloomberg
10:17AM	Hoth Therapeutics' Novel Cancer Drug Prevented Cell Growth, Induced Cell Death Over 72 hours Benzinga
09:47AM	BioMed Leaders: Hoth Therapeutics, Nova Mentis Life Sciences, Tonix Pharmaceuticals, and MedAvail; Visionary CEOs Report Latest Advances in Novel Therapeutics for Autism, Cancer, and Fibromyalgia, and Drug Affordability. GlobeNewswire
08:05AM	Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-KIT, Proves Effective Against Aggressive Cancer Cells PR Newswire
07:57AM	Midday Stock Movers: Hoth Therapeutics and Veru Soar Investing.com
06:21AM	Hoth Therapeutics Doubles After Tests Show Cancer Trial Drug Is Effective Investing.com
Apr-01-22 08:02AM	Hoth Therapeutics Announces Pipeline Presentation at the 2022 BIO International Convention PR Newswire
Mar-22-22 09:48AM	Hoth Therapeutics Announces it Has Successfully Completed Manufacturing Feasibility of the HT-KIT Drug Substance PR Newswire +5.69%
Mar-11-22 08:00AM	Hoth Therapeutics Announces Orphan Drug Designation Granted to Cancer Therapeutic HT-KIT to Treat Mastocytosis PR Newswire -23.43%
Feb-09-22 10:10AM	Hoth Therapeutics Announces the selection of NUVISAN for Manufacturing HT-001 Drug Batches for CLEER-001 Clinical Study for Cancer Patients PR Newswire
Feb-07-22 08:02AM	Hoth Therapeutics Announces Presentation of the HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data at the 2022 Alzheimer's Association International Conference PR Newswire -6.21%
Jan-31-22 08:17AM	Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board PR Newswire +7.78%
Jan-05-22 05:18AM	Will Hoth Therapeutics (NASDAQ:HOTH) Spend Its Cash Wisely? Simply Wall St. -10.77%
Jan-04-22 02:13PM	HOTH Stock Alert: Why Is Hoth Therapeutics Skyrocketing Today? InvestorPlace +84.50%
08:01AM	Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid in Alzheimer's Disease PR Newswire
Dec-21-21 07:59AM	Hoth Therapeutics Announces Submission of Orphan Drug Designation Request for HT-KIT to Treat Mastocytosis PR Newswire
Dec-08-21 08:00AM	Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics PR Newswire
Nov-30-21 08:00AM	Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under Way PR Newswire
Nov-16-21 08:30AM	Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KIT PR Newswire
Nov-08-21 08:38AM	Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer Therapeutic PR Newswire
Oct-19-21 12:47PM	Hoth Therapeutics Extends Partnership Agreement with REPROCELL PR Newswire
Oct-12-21 10:04AM	Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans Benzinga
10:00AM	Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis Patients PR Newswire
Sep-22-21 07:00AM	Hoth Therapeutics, Inc.: Invitation to the Benzinga Healthcare Small Cap Conference Newsfile
Sep-21-21 10:05AM	Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Trial PR Newswire
Sep-08-21 08:02AM	Hoth Therapeutics Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexa PR Newswire
07:56AM	EXCLUSIVE: Hoth Reports Safety Data From Early-Stage Study Of BioLexa Platform In Eczema Benzinga
Aug-11-21 09:01AM	Hoth Therapeutics' mRNA 'Frameshifting' Therapy HT-KIT for Mast Cell Cancers Reduces Size, Spread - Research Published in Molecular Therapy PR Newswire
Aug-02-21 08:15AM	Hoth Therapeutics Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease PR Newswire +5.43%
Jul-13-21 10:13AM	Hoth Therapeutics' HT-003 Shows Encouraging Action Against Acne In Animal Model Benzinga
08:15AM	Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against Acne PR Newswire
Jun-28-21 08:01AM	Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis PR Newswire
Jun-13-21 11:23PM	Is Hoth Therapeutics, Inc. (HOTH) A Good Stock To Buy Now? Insider Monkey
Jun-10-21 04:16AM	Companies Like Hoth Therapeutics (NASDAQ:HOTH) Are In A Position To Invest In Growth Simply Wall St.
Jun-07-21 02:31PM	Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic HT-ALZ PR Newswire +12.90%
Jun-03-21 12:32PM	Hoth Therapeutics Unveils Preclinical Results of HT-KIT Therapeutic Program Benzinga
08:01AM	Hoth Therapeutics Shares Positive Preclinical Results of Novel HT-KIT Therapeutic PR Newswire
Jun-01-21 08:05AM	Hoth Therapeutics Plans Shareholder Presentation on HT-KIT Therapeutic's Preclinical Results for Rare Cancers PR Newswire +5.52%
May-24-21 08:01AM	Hoth Therapeutics Announces Participation at the American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire -6.04%
May-13-21 08:28AM	Hoth Therapeutics Provides Shareholder Update on Novel Endocannabinoid Therapeutic for Cutaneous Lupus Erythematosus PR Newswire
May-05-21 09:24AM	Hoth Therapeutics and Virginia Commonwealth University Expand Research Agreement for COVID-19 Therapeutic PR Newswire +6.34%
May-03-21 09:13AM	Hoth Therapeutics Announces Development of HT-KIT to Treat Multiple Orphan Diseases, Including Rare Cancers PR Newswire
Apr-22-21 09:01AM	Hoth Therapeutics' First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa is Underway PR Newswire
Apr-20-21 09:06AM	Hoth Therapeutics Announces its mRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth in Mast Cell-Derived Cancers PR Newswire +5.48%
Apr-13-21 08:00AM	Voltron Therapeutics, Inc. Announces COVID-19 and Pandemic Preparedness Presentation to Congressional Offices and Agencies, Including HHS, NIH, FDA, and DoD GlobeNewswire
Apr-12-21 09:15AM	Hoth Therapeutics Completes HT-001 Formulation Development for Upcoming Cancer Patient Clinical Trial PR Newswire -6.74%
Apr-06-21 09:15AM	Hoth Therapeutics Engages Worldwide Clinical Trials as Contract Research Organization for Phase 2a HT-001 Clinical Trial for Cancer Patients PR Newswire -7.94%
Apr-05-21 08:01AM	Hoth Therapeutics, Inc. Announces Notice of Allowance for a New Patent Application Related to A Method for Inhibiting Formation of a Biofilm PR Newswire +5.42%
Mar-24-21 10:26AM	Hoth Therapeutics' Partner Voltron Therapeutics Reports Encouraging Preclinical Data From COVID-19 Vaccine Candidate Benzinga -11.95%
08:00AM	Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19 GlobeNewswire
Mar-23-21 08:01AM	Hoth Therapeutics Announces Positive Preclinical Results for Novel COVID-19 Therapeutic PR Newswire +15.14%
Mar-22-21 08:00AM	Hoth Therapeutics to Present at the Benzinga Biotech Small Cap Conference on March 24, 2021 PR Newswire
Mar-19-21 07:00AM	Hoth Therapeutics CEO, Robb Knie, Featured on the RedChip Money Report on Bloomberg TV this Saturday, March 20th PR Newswire
Mar-17-21 02:20PM	Hoth Therapeutics Inks Research Pact For Critical Studies Of HT-006 Antibiotic Benzinga
01:24PM	Hoth Therapeutics Partners with University of Cincinnati to Perform Critical Studies for Streamlined Development of Novel Antibiotic HT-006 PR Newswire
Mar-11-21 09:15AM	Hoth Therapeutics Executes Agreement to Assess the Effect of HT-003 Therapeutic Platform on Ulcerative Colitis and Crohn's Disease PR Newswire +7.89%
Mar-10-21 03:50PM	Hoth Therapeutics Completes Closing of Previously Announced $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules PR Newswire
Mar-08-21 05:00PM	Hoth Therapeutics Announces $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules PR Newswire
Mar-03-21 08:01AM	Hoth Therapeutics Provides Update on Novel Peptide COVID-19 Therapeutic HT-002 Preclinical Studies PR Newswire
Mar-01-21 03:02PM	Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis PR Newswire
Feb-26-21 11:05AM	Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment PR Newswire
Feb-25-21 09:55AM	Hoth Therapeutics Retains RedChip to Increase Investor Awareness PR Newswire -13.11%
Feb-24-21 10:20AM	Hoth Therapeutics Expands Intellectual Property Portfolio with Novel Alzheimer's Treatment PR Newswire +8.10%
Feb-23-21 08:02AM	Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of HT-001 For Cancer Patients PR Newswire +7.39%
Feb-18-21 09:27AM	Hoth Therapeutics Plans To Test HT-003 API In Inflammatory Bowel Disorders; Shares Spike Benzinga -12.17%
08:01AM	Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of Inflammatory Bowel Diseases (IBDs) PR Newswire
Feb-17-21 09:00AM	Diamond Equity Research Emerging Growth Invitational Winter 2021 Virtual Conference ACCESSWIRE +22.09%
08:00AM	Hoth Therapeutics to Present at the Diamond Equity Research Emerging Growth Invitational 2021 Virtual Conference PR Newswire
Feb-10-21 01:30PM	Hoth Therapeutics Scientific Advisory Board Member, Michael Peters, Ph.D., Publishes Whitepaper Regarding COVID-19 SARS-CoV-2 in bioRxiv PR Newswire
Feb-09-21 08:00AM	Voltron Therapeutics, Inc. Initiates Additional Animal Testing of Self-Assembling Vaccine in Fight Against COVID-19 GlobeNewswire
Feb-08-21 02:51PM	Hoth Therapeutics Partners with Camargo Pharmaceutical Services for the HT-001 IND, a Treatment for Cancer Patients PR Newswire +7.14%
Feb-02-21 08:45AM	Hoth Therapeutics Provides Operational Update on Novel Therapeutic Pipeline PR Newswire
Jan-28-21 08:02AM	Hoth Therapeutics Expands Research Collaboration Agreement with Weill Cornell Medicine to Continue the Advancement of HT-003 for Acne Treatment Research PR Newswire
Jan-27-21 08:31AM	Hoth Therapeutics Announces the Appointment of Mario E. Lacouture, M.D. to Oversee Dermatology Therapeutic Program for Cancer Patients as Part of Hoth Scientific Advisory Board PR Newswire -9.72%
Jan-20-21 08:38AM	Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for HT-003 In Pursuit for Acne Treatment Indication PR Newswire
Jan-13-21 08:01AM	FDA Grants Hoth Therapeutics Pre-IND Meeting Regarding Proposed Drug Development Plan for HT-001 Treatment for Cancer Patients PR Newswire
Jan-11-21 08:02AM	Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for Cancer Patients PR Newswire
Jan-05-21 09:00AM	Hoth Therapeutics Announces Private Placement of Equity Priced At-The-Market Under Nasdaq Rules PR Newswire -8.37%
Jan-04-21 08:01AM	Hoth Therapeutics Announces Licensing Agreement and Collaboration with U.S. Army Medical Research and Development Command (USAMRDC) for Treating Multi-Drug Resistant Bacterial Lung Infections PR Newswire +5.91%
Dec-31-20 08:01AM	Hoth Therapeutics Announces Production of HT-001 for Cancer Treatment PR Newswire +44.51%
Dec-23-20 09:55AM	Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND) Meeting for HT-001, Treatment for Cancer Patients PR Newswire
Dec-21-20 08:30AM	Endocannabinoid Pathway Targeted Drug Demonstrates Proof-of-Concept Efficacy in a Cutaneous Lupus Erythematosus Mouse Model PR Newswire
Dec-10-20 10:11AM	Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans PR Newswire +11.52%
Nov-16-20 11:30AM	Voltron Therapeutics, Inc. to Participate in the 2020 Fall Defense TechConnect Virtual Innovation Summit GlobeNewswire
Nov-03-20 09:25AM	Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease PR Newswire +5.45%
Nov-02-20 10:16AM	Hoth Therapeutics Provides Update for Novel COVID-19 Therapeutic, On-the-Go SARS-CoV-2 Testing Device, and Vaccine PR Newswire
Oct-20-20 10:30AM	Hoth Therapeutics Announces USPTO Grant of Patent for Targeted 13-Cis-RAMBA Retinamides for Development as a Novel Cancer Therapeutic PR Newswire
Sep-24-20 08:38AM	Hoth Therapeutics Announces its HT-003 Shows Positive Initial Data Inhibiting Toll-like Receptor 2 (TLR2) PR Newswire

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylo Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience